AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Increased bactericidal activity but dose-limiting tolerability at 50 mg/kg rifampicinView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacogenetics and pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TBView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Co-administration of pretomanid with rifampin or rifabutin among patients with pulmonary TB: interim PK results from “Assessing Pretomanid for Tuberculosis” (APT) trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with drug-resistant TBView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Evaluating hepatotoxicity of bedaquiline treatment in multi-drug resistant tuberculosis patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019An assessment of the effects of dolutegravir on gene expression and levonorgestrel clearance in human hepatocytes in vitroView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Cobicistat (COBI)-boosted Protease Inhibitors (PIs) plasma and intracellular (IC) pharmacokinetics (PK) in nicotine usersView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Glecaprevir/pibrentasvir pharmacokinetics in HCV/HIV patients co-administered with antiretroviral drugsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019The valproic acid – dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevantView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Valproic acid co-administration is not associated with lower non-dolutegravir antiretrovirals’ exposuresView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Short-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir containing antiviral regimens: a case seriesView Abstract
